| Market Cap | 257.85M | P/E | - | EPS this Y | -60.60% | Ern Qtrly Grth | - |
| Income | -199.92M | Forward P/E | -2.03 | EPS next Y | 22.50% | 50D Avg Chg | -30.00% |
| Sales | - | PEG | -0.02 | EPS past 5Y | - | 200D Avg Chg | -6.00% |
| Dividend | N/A | Price/Book | 4.52 | EPS next 5Y | 85.00% | 52W High Chg | -49.00% |
| Recommedations | 2.30 | Quick Ratio | 2.81 | Shares Outstanding | 57.95M | 52W Low Chg | 127.00% |
| Insider Own | 4.45% | ROA | -26.32% | Shares Float | 55.37M | Beta | 1.48 |
| Inst Own | 43.31% | ROE | - | Shares Shorted/Prior | 11.84M/11.69M | Price | 3.95 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 665,119 | Target Price | 43.00 |
| Oper. Margin | - | Earnings Date | Nov 7 | Volume | 506,467 | Change | -5.28% |
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
| Needham | Hold | Jun 4, 24 |
| Needham | Hold | May 16, 24 |
| Cantor Fitzgerald | Neutral | Nov 10, 23 |
| UBS | Neutral | Dec 8, 22 |
| B of A Securities | Underperform | Nov 8, 22 |
| B of A Securities | Neutral | Jun 8, 22 |
| HC Wainwright & Co. | Buy | Oct 19, 21 |
| JP Morgan | Underweight | Oct 8, 21 |
| HC Wainwright & Co. | Buy | Oct 6, 21 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Demopulos Gregory A MD | Chairman, CEO & Pres.. Chairman, CEO & President | Nov 17 | Buy | 1.68 | 15,000 | 25,200 | 123,945 | 11/21/23 |
| Demopulos Peter A MD | Director Director | Nov 15 | Buy | 1.53 | 10,000 | 15,300 | 208,516 | 11/17/23 |
| HANISH ARNOLD C | Director Director | May 22 | Sell | 6.46 | 5,000 | 32,300 | 05/23/23 | |
| HANISH ARNOLD C | Director Director | May 22 | Option | 5.3 | 5,000 | 26,500 | 5,000 | 05/23/23 |
| Cable Thomas J. | Director Director | May 22 | Sell | 6.53 | 5,000 | 32,650 | 35,067 | 05/23/23 |
| Cable Thomas J. | Director Director | May 22 | Option | 5.3 | 5,000 | 26,500 | 40,067 | 05/23/23 |
| Demopulos Gregory A MD | CHAIRMAN, CEO & PRES.. CHAIRMAN, CEO & PRESIDENT | Jun 17 | Option | 4.1 | 73,713 | 302,223 | 2,063,843 | 06/17/21 |
| Demopulos Gregory A MD | CHAIRMAN, CEO & PRES.. CHAIRMAN, CEO & PRESIDENT | Apr 08 | Option | 4.1 | 72,613 | 297,713 | 2,062,192 | 04/08/21 |
| Demopulos Gregory A MD | CHAIRMAN, CEO & PRES.. CHAIRMAN, CEO & PRESIDENT | Apr 08 | Sell | 17.84 | 72,613 | 1,295,416 | 2,026,986 | 04/08/21 |
| Demopulos Peter A MD | Director Director | Feb 23 | Option | 4.92 | 10,000 | 49,200 | 198,516 | 02/23/21 |